Of the hundreds of potential COVID-19 vaccines in development, six are in the final stages of testing, known as phase 3 clinical trials. One of these – ChAdOx1 nCoV-19 – is the vaccine we’re developing at the University of Oxford.
To be approved, vaccines need to go through multiple rounds of testing to show that they’re safe and effective. A combined phase 1 and phase 2 trial of the Oxford vaccine has demonstrated that it is safe – with only short-term side-effects and no serious unexpected events reported – and that it elicits an immune response.
The purpose of a phase 3 trial is to assess whether this vaccine-induced immune response is strong enough to actually protect people from COVID-19. Proving this would pave the way for the vaccine to become publicly available.
Oxford is a subscribing member of The Conversation. Find out how you can write for The Conversation.